Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 8, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and apatorsen (OGX-427), and announced second quarter 2013 financial results.

Custirsen Program Update

  • The primary registration Phase 3 SYNERGY trial, designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC), completed enrollment in 2012. As a result of death events occurring more slowly than previously expected, the anticipated timing of the pre-specified number of events is currently projected to occur late in the first quarter or early in the second quarter of 2014. These survival results are expected to be announced in mid-2014. No conclusion regarding the possible outcome of the trial can or should be drawn from the fact that death events are occurring more slowly than expected.
  • Patient enrollment continues in the additional Phase 3 custirsen trials, AFFINITY and ENSPIRIT. The AFFINITY trial will evaluate the potential survival benefit of custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in men with metastatic CRPC, and ENSPIRIT will evaluate the potential survival benefit of combining custirsen with docetaxel as second-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
  • Apatorsen (OGX-427) Program Update

  • The Company announced that the United States Adopted Names Council has approved the use of the nonproprietary generic name "apatorsen" for OGX-427.
  • In July 2013, the Company announced that enrollment has been completed in Borealis-1™, a comp
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
    (Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
    (Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
    ...  National data center hosting provider, CoreLink ... technology consulting firm, Burwood Group Inc., on Feb. ... the 2012 Annual HIMSS Conference & Exhibition in ... importance of disaster recovery planning in ...
    ... Anlit Advanced Nutrition Supplements , an innovative developer of ... start selling its products in Poland under the ... its wide variety of supplements for kids through a partnership ... natural healing products. Laboratoria Natury was acquired last year by ...
    Cached Medicine Technology:National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 2National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 3National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 4Anlit Enters Polish Market with New Food Supplements for Kids 2
    (Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
    (Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
    (Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
    (Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
    (Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
    Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
    ... as primary prevention did not appear to significantly reduce ... cerebrovascular and peripheral vascular events in patients with type ... JAMA . However, aspirin did significantly reduce the combination ... is being released early online Sunday, November 9 to ...
    ... of a new Chantix risk that may be causing patients to ... well. In addition to seizures, Chantix has also been under investigation ... ... Denver (PRWEB) November 4, 2008 -- LegalView, the number one ...
    ... for MP3 players placed within an inch of pacemakers ... devices, according to research presented at the American Heart ... effects of MP3 player headphones, most of which contain ... cardiac devices (abstract P662). , An MP3 player is ...
    ... Pa., Nov. 9 The NHS Human,Services Foundation held ... 2008 at the Hyatt Regency Penn,s Landing in Philadelphia. ... Foundation, which supports the mission,of NHS Human Services, one ... the country., Every year the Foundation presents the ...
    ... Glaucoma-related highlights of today,s scientific program of the 2008 ... and European Society of Ophthalmology (SOE) include a study ... carotid artery narrowing and potentially elevated risk for stroke, ... of fasting, common to the world,s seven major religions, ...
    ... of patients in need of organ transplants on the ... unconventional sources for organs. Individuals are willing to donate ... where the poverty rate is high, resulting in numerous ... This troubling issue will be the topic of a ...
    Cached Medicine News:Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 2Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 3Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 4Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 2Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 3Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 4Health News:MP3 headphones interfere with implantable defibrillators, pacemakers 2Health News:MP3 headphones interfere with implantable defibrillators, pacemakers 3Health News:Gala Raises Funds for NHS Human Services 2Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 2Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 3Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 4Health News:Transplant experts convene at ASN Renal Week 2008 to discuss organ trafficking 2
    ... offers an economical, ... alternative to existing ... guarantees accurate and ... the time-consuming recalibration ...
    ... 1296-041 DELFIA Plate Dispense allows the ... to all wells or to selected ... To minimize background and to avoid ... optimized for use with DELFIA Enhancement ...
    ... Precision 2000 ... innovative solution for ... liquid handling. With ... perform virtually any ...
    Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
    Medicine Products: